Welcome to our dedicated page for Merck & Co news (Ticker: MRK), a resource for investors and traders seeking the latest updates and insights on Merck & Co stock.
Merck & Co., Inc. (NYSE: MRK), known as MSD outside the United States and Canada, generates frequent news across human health, animal health and corporate finance. As a research-intensive biopharmaceutical company with more than a century of history developing medicines and vaccines, Merck regularly announces clinical trial milestones, regulatory decisions, business development transactions and capital markets activity.
Recent news highlights include oncology updates from Merck’s extensive KEYTRUDA program, such as positive Phase 3 data in muscle-invasive bladder cancer and new trials in non-small cell lung cancer using combinations like calderasib (MK-1084) with KEYTRUDA QLEX. The company also reports on progress in other therapeutic areas, including pulmonary arterial hypertension with WINREVAIR, Alzheimer’s disease candidates MK-2214 and MK-1167, and cardiovascular research with the oral PCSK9 inhibitor candidate enlicitide.
Investors following MRK news will also see announcements related to Merck Animal Health, such as the conditional U.S. FDA approval of EXZOLT CATTLE-CA1 for the prevention and treatment of New World screwworm larvae and the treatment and control of cattle fever tick, as well as updates on acquisitions like the planned merger with Cidara Therapeutics to add the influenza candidate CD388 to Merck’s respiratory portfolio.
Corporate and financial communications include quarterly earnings calls, participation in major healthcare conferences and disclosures about note offerings under the company’s shelf registration statement. This news page aggregates these developments so readers can review clinical, regulatory, strategic and financial updates related to Merck & Co., Inc. and its MRK stock in one place.
Merck (NYSE: MRK) announced that its Phase 3 KEYNOTE-522 trial met its overall survival (OS) endpoint for patients with high-risk early-stage triple-negative breast cancer (TNBC) using KEYTRUDA (pembrolizumab). The regimen, combining pre-operative chemotherapy with subsequent monotherapy, showed a statistically significant improvement in OS. The safety profile was consistent with previous studies, with no new safety signals. KEYTRUDA is now the first immunotherapy-based treatment to provide a survival benefit over chemotherapy alone in this patient group. These results, building on previous positive outcomes, will be presented at a medical meeting and shared with regulatory authorities.
Merck (NYSE: MRK) will present new data on its oncology treatments at the 2024 ASCO Annual Meeting from May 31-June 4. Highlights include Phase 3 results for sacituzumab tirumotecan in metastatic triple-negative breast cancer and three-year follow-up data for mRNA-4157 (V940) combined with KEYTRUDA in high-risk melanoma patients. Other key data involve updated findings for KEYTRUDA in various cancers, including advanced gastrointestinal cancers and metastatic bladder cancer. Merck's diverse oncology pipeline will also be showcased, featuring investigational treatments such as vibostolimab/pembrolizumab and sacituzumab tirumotecan. The company will hold an Oncology Investor Event on June 3, 2024, to discuss these developments.
Merck (MRK) announced the discontinuation of the vibostolimab and pembrolizumab coformulation arm of the Phase 3 KeyVibe-010 trial for adjuvant treatment of resected high-risk melanoma due to primary endpoint not met. Patients in the coformulation arm had higher discontinuation rates mainly due to immune-mediated adverse experiences. The study is being unblinded, and patients are recommended to switch to KEYTRUDA monotherapy. Merck remains committed to developing new melanoma treatments and is exploring other combinations. Vibostolimab is an investigational anti-TIGIT antibody under evaluation.
Merck provided an update on the Phase 3 KEYNOTE-B21 trial evaluating KEYTRUDA in combination with chemotherapy for patients with high-risk endometrial cancer. The trial did not meet its primary endpoint of disease-free survival. The safety profile of KEYTRUDA was consistent with previous studies. Merck will continue to expand the role of KEYTRUDA in endometrial cancer treatment.
Merck (NYSE:MRK) has exceeded its goal of reaching 25 million women by 2025 through its global maternal health initiative, Merck for Mothers, now reaching over 30 million women worldwide. The initiative supports the UN's Sustainable Development Goal 3 by focusing on reducing maternal mortality rates and improving access to health care. Through public-private collaborations in over 70 countries, Merck for Mothers has made significant impacts in countries like India, Brazil, Kenya, Nigeria, and the United States.
Merck, trading as MRK on NYSE, will have its CFO participate in a fireside chat at the Bank of America Securities 2024 Healthcare Conference on May 15, 2024. The event will be broadcast live for investors, analysts, and the public.
Merck (MRK) announced that the Phase 3 KEYNOTE-811 trial evaluating KEYTRUDA® met its dual primary endpoint of overall survival (OS) for the first-line treatment of patients with HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma. The trial showed a statistically significant and clinically meaningful improvement in OS compared to placebo, with encouraging results from the progression-free survival, overall response rate, and duration of response data. Merck continues to study KEYTRUDA in gastrointestinal cancers for multiple uses.
Merck (NYSE: MRK) announced positive results from the Phase 3 STRIDE-10 trial evaluating V116, an adult-specific 21-valent pneumococcal conjugate vaccine. The trial showed noninferior immune responses compared to PPSV23 for common serotypes, superior responses for unique serotypes, and a safety profile comparable to PPSV23. The data support V116 as a potential preventative option for invasive pneumococcal disease in adults.
Summary not available.
Summary not available.